MoST Substudy 1: Single arm, open label, signal seeking, phase Ib/IIa trial of the CDK4/6 inhibitor palbociclib in patients with tumours with amplified D-type cyclins or CDK4 or inactivation of CDKN2A
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Palbociclib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms MoST Substudy 1
- 31 Aug 2023 Results from DRUP and Australian MoST , for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib published in the International Journal of Cancer
- 06 Jun 2023 Results (n=139) assessing efficacy and safety of of palbociclib and ribociclib monotherapy in advanced cancers in the Dutch DRUP and Australian MoST trials, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 17 Feb 2020 Status changed from active, no longer recruiting to completed.